FinscoFinsco

Emergent BioSolutions (US.EBS)

Capital Allocation Audit · Period: 2010 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.EBS · YoY: 2026 H1 vs 2025 H1

MetricValueYoY
FCF Conversion79.8%↓
ROE-50.8%↓
Cash Conversion-→
D/E Ratio1.70↓
Gross Margin53.1%→
US.EBS (Emergent BioSolutions) | YoY: 2026 H1 vs 2025 H1


Metric            Value  YoY
----------------------------
FCF Conversion    79.8%    ↓
ROE              -50.8%    ↓
Cash Conversion       -    →
D/E Ratio          1.70    ↓
Gross Margin      53.1%    →
Key Metrics
US.EBS (Emergent BioSolutions) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY
----------------------------
FCF Conversion 79.8% ↓
ROE -50.8% ↓
Cash Conversion - →
D/E Ratio 1.70 ↓
Gross Margin 53.1% →

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies